Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Inhibition of MicroRNA-494 Reduces Carotid Artery Atherosclerotic Lesion Development and Increases Plaque Stability.

Wezel A, Welten SM, Razawy W, Lagraauw HM, de Vries MR, Goossens EA, Boonstra MC, Hamming JF, Kandimalla ER, Kuiper J, Quax PH, Nossent AY, Bot I.

Ann Surg. 2015 Nov;262(5):841-7; discussion 847-8. doi: 10.1097/SLA.0000000000001466.

PMID:
26583674
2.

Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms.

Pelka K, Phulphagar K, Zimmermann J, Stahl R, Schmid-Burgk JL, Schmidt T, Spille JH, Labzin LI, Agrawal S, Kandimalla ER, Casanova JL, Hornung V, Marshak-Rothstein A, Höning S, Latz E.

J Immunol. 2014 Oct 1;193(7):3257-61. doi: 10.4049/jimmunol.1301886. Epub 2014 Sep 3.

3.

Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia.

Welten SM, Bastiaansen AJ, de Jong RC, de Vries MR, Peters EA, Boonstra MC, Sheikh SP, La Monica N, Kandimalla ER, Quax PH, Nossent AY.

Circ Res. 2014 Sep 26;115(8):696-708. doi: 10.1161/CIRCRESAHA.114.304747. Epub 2014 Aug 1.

4.

Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle.

Henriques-Pons A, Yu Q, Rayavarapu S, Cohen TV, Ampong B, Cha HJ, Jahnke V, Van der Meulen J, Wang D, Jiang W, Kandimalla ER, Agrawal S, Spurney CF, Nagaraju K.

Hum Mol Genet. 2014 May 15;23(10):2604-17. doi: 10.1093/hmg/ddt656. Epub 2013 Dec 23.

5.

A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.

Zhu FG, Jiang W, Bhagat L, Wang D, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S.

Autoimmunity. 2013 Nov;46(7):419-28. doi: 10.3109/08916934.2013.798651. Epub 2013 Jun 12.

PMID:
24083389
6.

Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Putta MR, Bhagat L, Wang D, Zhu FG, Kandimalla ER, Agrawal S.

ACS Med Chem Lett. 2013 Jan 29;4(2):302-5. doi: 10.1021/ml300482z. eCollection 2013 Feb 14.

7.

Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.

Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N, Agrawal S.

Nucleic Acids Res. 2013 Apr 1;41(6):3947-61. doi: 10.1093/nar/gkt078. Epub 2013 Feb 8.

8.

Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins.

Reed JH, Jain M, Lee K, Kandimalla ER, Faridi MH, Buyon JP, Gupta V, Clancy RM.

J Biol Chem. 2013 Mar 29;288(13):9077-83. doi: 10.1074/jbc.M112.403303. Epub 2013 Feb 5.

9.

A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.

Jiang W, Zhu FG, Bhagat L, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S.

J Invest Dermatol. 2013 Jul;133(7):1777-84. doi: 10.1038/jid.2013.57. Epub 2013 Jan 31.

10.

Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo.

Lan T, Wang D, Bhagat L, Philbin VJ, Yu D, Tang JX, Putta MR, Sullivan T, La Monica N, Kandimalla ER, Agrawal S.

Org Biomol Chem. 2013 Feb 14;11(6):1049-58. doi: 10.1039/c2ob26946e. Epub 2013 Jan 4.

PMID:
23292214
11.

Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist.

Makowska Z, Blumer T, Duong FH, La Monica N, Kandimalla ER, Heim MH.

J Hepatol. 2013 Apr;58(4):743-9. doi: 10.1016/j.jhep.2012.11.038. Epub 2012 Dec 1.

PMID:
23207140
12.

An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.

Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C.

PLoS One. 2012;7(5):e38111. doi: 10.1371/journal.pone.0038111. Epub 2012 May 30.

13.

Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration.

Karper JC, Ewing MM, Habets KL, de Vries MR, Peters EA, van Oeveren-Rietdijk AM, de Boer HC, Hamming JF, Kuiper J, Kandimalla ER, La Monica N, Jukema JW, Quax PH.

Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):e72-80. doi: 10.1161/ATVBAHA.112.249391. Epub 2012 May 24.

14.

TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome.

Saha S, Bhanja P, Liu L, Alfieri AA, Yu D, Kandimalla ER, Agrawal S, Guha C.

PLoS One. 2012;7(1):e29357. doi: 10.1371/journal.pone.0029357. Epub 2012 Jan 4.

15.

Synthesis, purification, and characterization of immune-modulatory oligodeoxynucleotides that act as agonists of Toll-like receptor 9.

Putta MR, Yu D, Kandimalla ER.

Methods Mol Biol. 2011;764:263-77. doi: 10.1007/978-1-61779-188-8_18.

PMID:
21748647
16.

Synthesis, purification, and characterization of oligoribonucleotides that act as agonists of TLR7 and/or TLR8.

Lan T, Kandimalla ER.

Methods Mol Biol. 2011;764:249-61. doi: 10.1007/978-1-61779-188-8_17.

PMID:
21748646
17.

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR.

Cell Immunol. 2011;270(2):126-34. doi: 10.1016/j.cellimm.2011.03.027. Epub 2011 Apr 22.

PMID:
21570062
18.

Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity.

Bhagat L, Putta MR, Wang D, Yu D, Lan T, Jiang W, Sun Z, Wang H, Tang JX, La Monica N, Kandimalla ER, Agrawal S.

J Med Chem. 2011 Apr 28;54(8):3027-36. doi: 10.1021/jm200113t. Epub 2011 Apr 5.

PMID:
21466154
19.

Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER, Agrawal S.

Mol Cancer Ther. 2010 Jun;9(6):1788-97. doi: 10.1158/1535-7163.MCT-09-1198. Epub 2010 Jun 1.

20.

Synthesis and immunological activities of novel agonists of toll-like receptor 9.

Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR.

Cell Immunol. 2010;263(1):105-13. doi: 10.1016/j.cellimm.2010.03.005. Epub 2010 Mar 10.

PMID:
20381019
21.

Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.

Putta MR, Yu D, Bhagat L, Wang D, Zhu FG, Kandimalla ER.

J Med Chem. 2010 May 13;53(9):3730-8. doi: 10.1021/jm100177p.

PMID:
20361743
22.

A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.

Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L.

Vaccine. 2010 Apr 30;28(20):3522-30. doi: 10.1016/j.vaccine.2010.03.020. Epub 2010 Mar 21.

PMID:
20332048
23.

Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity.

Putta MR, Zhu FG, Wang D, Bhagat L, Dai M, Kandimalla ER, Agrawal S.

Bioconjug Chem. 2010 Jan;21(1):39-45. doi: 10.1021/bc900425s.

PMID:
20020767
24.

A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.

Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G.

Clin Cancer Res. 2009 Nov 15;15(22):6921-30. doi: 10.1158/1078-0432.CCR-09-1599. Epub 2009 Nov 10.

25.

Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.

Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S.

J Med Chem. 2009 Nov 12;52(21):6871-9. doi: 10.1021/jm901145s.

PMID:
19824640
26.

Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.

Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S.

J Med Chem. 2009 Aug 27;52(16):5108-14. doi: 10.1021/jm900730r.

PMID:
19650625
27.

Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.

Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, Kandimalla ER, Agrawal S, Scarselli E, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L.

Mol Ther. 2009 Oct;17(10):1804-13. doi: 10.1038/mt.2009.165. Epub 2009 Jul 21. Erratum in: Mol Ther. 2010 Feb;18(2):447.

28.

Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.

Lan T, Putta MR, Wang D, Dai M, Yu D, Kandimalla ER, Agrawal S.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):443-8. doi: 10.1016/j.bbrc.2009.06.036. Epub 2009 Jun 11.

PMID:
19523922
29.

Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8.

Lan T, Bhagat L, Wang D, Dai M, Kandimalla ER, Agrawal S.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):2044-7. doi: 10.1016/j.bmcl.2009.02.021. Epub 2009 Feb 10.

PMID:
19269175
30.

Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.

Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N.

Clin Cancer Res. 2009 Mar 1;15(5):1575-84. doi: 10.1158/1078-0432.CCR-08-2628. Epub 2009 Feb 24.

31.

Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.

Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S.

J Med Chem. 2009 Jan 22;52(2):551-8. doi: 10.1021/jm8014316.

PMID:
19102653
32.

Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S.

Antimicrob Agents Chemother. 2008 Dec;52(12):4320-5. doi: 10.1128/AAC.00701-08. Epub 2008 Oct 13.

33.

Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro.

Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, Kandimalla ER, Yu D, Zurbriggen A, Doherr MG, Peel J, Roosje PJ.

Vet Immunol Immunopathol. 2008 Jul 15;124(1-2):120-31. doi: 10.1016/j.vetimm.2008.03.002. Epub 2008 Mar 20.

PMID:
18452997
34.

Chemistry of CpG DNA.

Kandimalla ER, Agrawal S.

Curr Protoc Nucleic Acid Chem. 2003 May;Chapter 4:Unit 4.16. doi: 10.1002/0471142700.nc0416s12.

PMID:
18428906
35.

Synthetic agonists of Toll-like receptors 7, 8 and 9.

Agrawal S, Kandimalla ER.

Biochem Soc Trans. 2007 Dec;35(Pt 6):1461-7. Review.

PMID:
18031246
36.

Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.

Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S.

J Med Chem. 2007 Dec 13;50(25):6411-8. Epub 2007 Nov 8.

PMID:
17988082
37.

Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.

Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu F, Tang JX, Putta MR, Cong Y, Trombino AF, Sullivan T, Agrawal S.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13750-5. Epub 2007 Aug 14.

38.

Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced eustachian tube dysfunction in rats.

Blanks DA, Ebert CS Jr, Eapen RP, Zdanski C, Kandimalla ER, Agrawal S, Prazma J.

Otolaryngol Head Neck Surg. 2007 Aug;137(2):321-6.

PMID:
17666264
39.

Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats.

Ebert CS Jr, Rose AS, Blanks DA, Eapen RP, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC 3rd.

Otolaryngol Head Neck Surg. 2007 Aug;137(2):250-5.

PMID:
17666251
40.

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12468-73. Epub 2007 Jul 16.

41.

Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice.

Zhu FG, Kandimalla ER, Yu D, Agrawal S.

J Allergy Clin Immunol. 2007 Sep;120(3):631-7. Epub 2007 Jun 20.

PMID:
17582479
42.

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.

LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP.

Clin Cancer Res. 2006 Sep 1;12(17):5231-41.

43.

The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction.

Ebert CS Jr, Rose AS, Patel MR, Hardy SM, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC 3rd.

Int J Pediatr Otorhinolaryngol. 2006 Dec;70(12):2019-26. Epub 2006 Aug 30.

PMID:
16939693
44.
45.

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R.

Mol Cancer Ther. 2006 Jun;5(6):1585-92.

46.

Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.

Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S.

Nucleic Acids Res. 2006 Jun 23;34(11):3231-8. Print 2006.

47.

Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640.

Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J.

Ann N Y Acad Sci. 2005 Nov;1058:215-34. Review.

PMID:
16394139
48.

Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.

Trabattoni D, Clivio A, Bray DH, Bhagat L, Beltrami S, Maffeis G, Cesana E, Lowry P, Lissoni F, Kandimalla ER, Sullivan T, Agrawal S, Bartholomew R, Clerici M.

Vaccine. 2006 Feb 27;24(9):1470-7. Epub 2005 Sep 22.

PMID:
16221513
49.

Therapeutic potential of synthetic CpG DNA--current status and future directions.

Kandimalla ER, Agrawal S.

IDrugs. 2001 Sep;4(9):963-6. No abstract available.

PMID:
15965830
50.

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S.

Proc Natl Acad Sci U S A. 2005 May 10;102(19):6925-30. Epub 2005 Apr 28.

Supplemental Content

Loading ...
Support Center